Clinical Trials Browser

Phase 2 × Interventional × Valganciclovir × Clear all

NCT00092222 2026-05-22

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Phase 2 Active not recruiting

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT07383649 2026-04-08

Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection

Phase 2 Recruiting

Brain Neoplasms

NCT04116411 2025-12-22

VIGAS2

Phase 2 Active not recruiting

Glioblastoma

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05011058 2025-07-28

NAVAL-1

Phase 2 Terminated

102 enrolled 28 charts

Epstein-Barr Virus Infections, Pyloric Stenosis, Hypertrophic

NCT01972035 2022-04-12

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

Phase 2 Completed

137 enrolled 8 charts

Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT03296553 2022-01-27

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

Phase 2 Completed

40 enrolled 6 charts

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Immune Reconstitution Inflammatory Syndrome

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Phase 2 Completed

8 enrolled 18 charts

LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

Phase 2 Withdrawn

GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

NCT00217503 2013-06-20

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Phase 2 Completed

Lymphoma

NCT00562770 2012-07-31

Oral Valganciclovir Versus Valacyclovir

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00917826 2011-08-01

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

Phase 2 Terminated

EBV Lymphomas

NCT00992732 2011-08-01

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

Phase 2 Terminated

Lymphoproliferative Disorders

NCT00194467 2008-01-10

Suppression of Oral HHV8 Shedding With Valganciclovir

Phase 2 Completed

Sarcoma, Kaposi